WB, IF-F, IF-IC
H M
Endogenous
57
Rabbit IgG
#Q9Y5Z0
25825
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunofluorescence (Frozen) | 1:400 - 1:1600 |
| Immunofluorescence (Immunocytochemistry) | 1:800 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human BACE2 protein.
Background
β-secretase 2 (BACE2) is a type I transmembrane aspartic acid protease that catalyzes the processing of its substrates, including amyloid precursor protein (APP). Pro-BACE2 is synthesized in the endoplasmic reticulum (ER) before it is transported to the trans-Golgi network where it is cleaved by furin to become its mature form. BACE2 then migrates to the plasma membrane where it acts upon its substrates (1,2). Mature BACE2 functions as a θ-secretase, cleaving APP to produce a carboxyl-terminal fragment of 80 amino acids (C80) (3,4). Similar to its homolog BACE, BACE2 can also cleave APP at the β-site, releasing a soluble, extracellular APP-β (sAPP-β) ectodomain and generating a membrane-bound, carboxy-terminal fragment consisting of 99 amino acids (C99). Mutations within the juxtamembrane helix (JH) of APP, or the binding of this region by the neuronal chaperone protein clusterin, enables this BACE2-mediated β-cleavage. Additional processing of C99 by γ-secretase generates the amyloid β-peptide (Aβ) that forms aggregates in the brains of Alzheimer's disease (AD) patients (5).
BACE2 expression in the brain is lower, both in comparison to that of BACE and to its expression level in the periphery. However, expression of BACE2 within the brain has been seen to increase during aging and in the context of neurodegenerative disease, further supporting the role it may play in disease progression (5,6). BACE2 may also play a role in disease progression in the periphery. For instance, in the pancreas, BACE2 has been implicated in regulating β-cell function and mass in the context of type II diabetes (2,7).
- Yan, R. (2017) Front Mol Neurosci 10, 97.
- Casas, S. et al. (2010) Am J Physiol Endocrinol Metab 299, E1087-95.
- Sun, X. et al. (2006) FASEB J 20, 1369-76.
- Qiu, K. et al. (2020) BMC Mol Cell Biol 21, 13.
- Wang, Z. et al. (2019) JCI Insight 4, e123431. doi: 10.1172/jci.insight.123431.
- Holler, C.J. et al. (2012) Am J Pathol 180, 337-50.
- Esterházy, D. et al. (2011) Cell Metab 14, 365-77.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IF-F: Immunofluorescence (Frozen) IF-IC: Immunofluorescence (Immunocytochemistry)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.